Plantamajoside improves type 2 diabetes mellitus pancreatic β-cell damage by inhibiting endoplasmic reticulum stress through Dnajc1 up-regulation

doi:10.4239/wjd.v16.i2.99053

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (212)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

HTML

126

Figures (1-7)

Sum=155

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=50

Feb 15, 2025 (publication date) through Jan 9, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Feb 15, 2025; 16(2): 99053
Published online Feb 15, 2025. doi: 10.4239/wjd.v16.i2.99053

Plantamajoside improves type 2 diabetes mellitus pancreatic β-cell damage by inhibiting endoplasmic reticulum stress through Dnajc1 up-regulation

Duo Wang, Yuan-Song Wang, Hong-Min Zhao, Peng Lu, Meng Li, Wei Li, Huan-Tian Cui, Zhong-Yong Zhang, Shu-Quan Lv

Duo Wang, Yuan-Song Wang, Hong-Min Zhao, Zhong-Yong Zhang, Shu-Quan Lv, Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province Affiliated to Hebei University of Chinese Medicine, Cangzhou 061000, Hebei Province, China

Peng Lu, Department of Endocrinology, Xianxian Hospital of Traditional Chinese Medicine of Hebei, Cangzhou 062250, Hebei Province, China

Meng Li, Graduate School, Hebei Medical University, Shijiazhuang 050011, Hebei Province, China

Wei Li, Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050299, Hebei Province, China

Huan-Tian Cui, The First School of Clinical Medicine, Yunnan University of Traditional Chinese Medicine, Kunming 065000, Yunnan Province, China

Zhong-Yong Zhang, Shu-Quan Lv, Zhong-Yong Zhang and Shu-Quan Lv.

Co-corresponding authors: Zhong-Yong Zhang and Shu-Quan Lv.

Author contributions: Wang D contributed to manuscript drafting, investigation, and funding acquisition; Wang YS contributed to manuscript drafting, investigation, validation, and data curation; Zhao HM contributed to investigation, validation, and data curation; Lu P and Li M contributed to manuscript drafting and formal analysis; Li W contributed to investigation and validation; Cui HT contributed to review and editing of the manuscript drafts, conceptualization; Zhang ZY, Lv SQ contributed to manuscript drafting, investigation, validation, data curation, validation, and conceptualization.

Supported by Yuansong Wang National Famous Traditional Chinese Medicine Expert Heritage Studio, No. 4 (2022).

Institutional review board statement: All experimental procedures received approval from Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province.

Institutional animal care and use committee statement: All experimental procedures followed the Guidelines for Animal Ethics and received approval from Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province (Approval Number: CZX2024-KY-052).

Conflict-of-interest statement: The authors declare no conflict of interests.

Data sharing statement: Data will be made available on reasonable request.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shu-Quan Lv, PhD, Doctor, Researcher, Department of Endocrinology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine of Hebei Province Affiliated to Hebei University of Chinese Medicine, No. 31 West Yellow River Road, Cangzhou 061000, Hebei Province, China. czlvshuquan@163.com

Received: July 12, 2024
Revised: October 26, 2024
Accepted: November 26, 2024
Published online: February 15, 2025
Processing time: 171 Days and 5.8 Hours

Core Tip

Core Tip: Plantamajoside (PMS) exhibits therapeutic effects in rats with type 2 diabetes mellitus pancreatic β-cell damage. The mechanism of action of PMS appears to involve Dnajc1 activation, which subsequently inhibits apoptosis and endoplasmic reticulum stress, ultimately ameliorating damage to pancreatic β-cells.